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Introduction to the Special Issue on viral channel forming proteinsCells have developed a special type of membrane proteins which
enables the ﬂux of ions across the lipid membrane. The proteins
oligomerize and form pores, which lower the energy barrier for ions to
pass the hydrophobic barrier imposed by the lipid membrane.
Substrate ﬂux does not consume any energy and is therefore in
contrast with protein induced "transport" processes. The mode of
action of channel proteins can be either triggered by gradients, ligands
or mechanical stress within the membrane.
Viruses hijack the cell and modulate the interior of the cell to
replicate their genomes. Similar to the host cells barriers such as the
lipid membrane have to be overcome so that ions can ﬂow across to
support the cellular life cycle of the virus. Consequently the same type
of proteins needs to be developed by the viruses, or the host channel
proteins have to be used and manipulated adequately. Since the
discovery of a channel that conducts protons in the genome of
inﬂuenza A viruses, the proton channel M2, similar proteins have
been proposed and detected in other viruses. It has also been shown
that some of the channel proteins also conduct larger molecules or
substrates. After almost 30 years of research on these proteins still
some open questions remain. So far for most of the viruses we do not
know why and also at which stage during the cellular life cycle they
need ion or substrate channelling. Claiming to be a substrate channel,
it is interesting to know whether these channels are speciﬁc for
certain substrates or even classes of substrates. The known channel
proteins are reported to be up to 100 amino acids in length, with one
exceptions of being 274 amino acids in length. Is there a relation
between speciﬁcity and size, and if so, then what structural feature is
responsible for this?What triggers channel activity? There is not yet a
single channel resolved in its entire length by X-ray crystallography or
NMR spectroscopy. However, parts of the proton channel have now
been reported on the atomic level ensemble within the lipid
membrane and even in the presence of drugs by both of the two
techniques mentioned.
For many viruses channel proteins are essential. Combating
inﬂuenza, its M2 proton channel has been one of the ﬁrst targets for
antiviral therapy. Interestingly, binding sites of drugs have been
reported to be within and outside the channel. However, not very
many drugs have been reported up to date targeting these channel
proteins. This may have two reasons. Firstly, targeting a membrane
protein, which is relatively small, with small molecules is a challenge
even for modern drug development. Secondly in many cases these
proteins are not that essential or have not yet been described as such.
Because of these reasons, other targets, usually the globular viral
proteins are on the top of the list being the target. With increasing
spread of retroviral diseases in combination with the enormous
mutation rate, viral channel proteins, called “soft targets,”may sooner0005-2736/$ – see front matter © 2010 Published by Elsevier B.V.
doi:10.1016/j.bbamem.2010.12.003or later move into the focus either as single target, in case they are
found to be essential for the viral life cycle, or as a peripheral target in
a drug cocktail.
This special issue aims to present a summary of the state of the art
on viral channel proteins written by experts in the ﬁeld. A general
overview of howmany channels exist is reported. Contributions cover
(K+-channels) channels encoded by plant viruses, a newly discovered
protein 8a from SARS-Co, which is found to exhibit channel activity,
and two proteins encoded by HIV-1 and HCV, Vpu and p7,
respectively, focusing on structural discoveries. In another contribu-
tion a link between sequence homology and structural features of Vpu
with known and structurally resolved host channels is presented. The
proton channel M2 from inﬂuenza A is discussed intensively in this
special issue. This especially since the discovery of structural features
within the lipid membrane on an atomic level by two groups using
different techniques has sparked exciting discussions about the
mechanism of function of this channel and its interaction with the
known antiviral drugs amantadine and its derivatives. Novel antiviral
drugs against M2 are reported and computer simulations of drug–
protein interactions of M2 are presented.
We wish to thank all researchers for their outstanding contribu-
tions and also the team of Biochimica and Biophysica Acta–
Biomembranes for their generous support which made this special
issue reality.
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